Madrigal Pharmaceuticals agreed to license six preclinical siRNA programs from Ribo Life Science and Ribocure to broaden its metabolic dysfunction-associated steatohepatitis (MASH) portfolio, paying $60 million upfront with up to $4.4 billion in milestones. The deal is designed to pair gene-silencing approaches with Madrigal’s approved thyroid receptor agonist Rezdiffra to address multiple drivers of fatty liver disease. Company executives framed the acquisition as a fast track to next-generation, liver-targeted combination strategies. The deal follows a pattern of dealmaking by Madrigal to convert a single-product launch into a diversified MASH franchise amid intensifying competition in the field.